Our founding story
AGADA Biosciences was founded in 2013 by Drs. Kanneboyina Nagaraju and Eric Hoffman as a spinout from the Children’s National Medical Center in Washington, D.C.
We were established to meet a practical need in rare disease drug development: more rigorous, reproducible scientific support at critical points in development.
That early work centered on robust standard operating procedures for preclinical outcome measures, alongside specialist methods for muscle biopsy analysis and bioassays.
Together, those foundations helped shape a model built around rigorous science, practical collaboration and support designed to reduce risk as programs moved forward.
Key milestones
Our history is rooted in scientific need and shaped by the evolving demands of rare disease drug development. These milestones highlight how that foundation has developed over time.
2013
AGADA Biosciences is founded
Drs. Kanneboyina Nagaraju and Eric Hoffman establish AGADA Biosciences as a spinout from Children’s National Medical Center in Washington, D.C., to provide specialist scientific support for rare disease drug development.
2014
Preclinical foundations take shape
Early work centres on robust standard operating procedures for preclinical outcome measures, helping address the need for more reproducible efficacy studies before potential therapies move into human clinical trials.
2017
Clinical and biopsy expertise expands
Our role grows to include specialist support around muscle biopsy analysis, stringent bioassays and clinical trial site training and processing for flash-frozen muscle biopsies.
2022
Capabilities broaden across critical stages
As client needs evolve, we expanded our support across preclinical and clinical settings, applying focused expertise at the points where rigorous scientific input can make the greatest difference.
TODAY
Agada supports rare disease programs with dedicated expertise, rigorous science and a collaborative, responsive approach shaped around the needs of each program.
Our mission
AGADA’s mission is to accelerate drug development by providing expert guidance in surrogate biomarkers and outcomes. We support sponsors in making informed drug development decisions by applying a depth of knowledge, robust experimental design, data generation and data interpretation to their preclinical and clinical projects and trials.
Get in touch
To learn how AGADA Biosciences could support your program, get in touch with our team and start the conversation.
Why AGADA?
We bring dedicated expertise to programs where there is little room for error, providing the scientific support, responsiveness and program fit that help rare disease teams move forward with clarity.
Decade of specialization:
Founded in 2013 as a spinout from Children’s National Medical Center to provide specialist scientific support for rare disease drug development.
Consistent audit success:
We successfully pass an average of five sponsor audits annually to support clinical trials across multiple phases.
Historical benchmarking:
We leverage archival data from over 100 trials in mouse models of muscular dystrophy to accurately power your efficacy studies.
Dedicated scale:
We operate with a team of approximately 50 employees, entirely focused on executing complex rare disease programs.
